Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma

Samara Potter¹, Jacquelyn Reuther², Raghu Chandramohan², Ilavarasi Gandhi², Faith Hollingsworth², Hadi Sayeed³, Horatiiu Voicu³, Nipun Kakkar¹, Koel Sen Baksi¹, Stephen Sarabia², Monica Lopez³, Daniel Chelius³, Ioanna Athanassaki², Priya Mahajan¹, Rajkumar Venkatramani³, Norma Quintanilla³, Dolores Lopez-Terrada², Angshumoy Roy³, and Donald Parsons²

¹Texas Children’s Cancer Center
²Baylor College of Medicine
³Texas Children’s Hospital

June 5, 2020

Abstract

Background: Pediatric papillary thyroid carcinoma (PTC) is clinically and biologically distinct from adult PTC. We sequenced a cohort of clinically-annotated pediatric PTC cases enriched for high-risk tumors to identify genetic alterations of relevance for diagnosis and therapy. Methods: Tumor DNA and RNA were extracted from FFPE tissue and subjected to next generation sequencing (NGS) library preparation using a custom 124 gene hybridization capture panel and the 75 gene Archer Oncology Research Panel, respectively. NGS libraries were sequenced on an Illumina MiSeq. Results: Thirty-six pediatric PTC cases were analyzed. Metastases were frequently observed to cervical lymph nodes (29/36, 81%), with pulmonary metastases less commonly found (10/36, 28%). Relapsed or refractory disease occurred in 18 patients (18/36, 50%). DNA sequencing revealed targetable mutations in 8 of 31 tumors tested (26%), most commonly BRAF p.V600E (n=6). RNA sequencing identified targetable fusions in 13 of 25 tumors tested (52%): RET (n=8), NTRK3 (n=4), and BRAF. Mutually-exclusive targetable alterations were discovered in 15 of the 20 tumors (75%) with both DNA and RNA analyzed. Fusion positive PTC was associated with multifocal disease, higher tumor staging, and higher American Thyroid Association (ATA) risk levels. Both BRAF V600E mutations and gene fusions were correlated with the presence of cervical metastases. Conclusions: Targetable alterations were identified in 75% of pediatric PTC cases with both DNA and RNA evaluated. Inclusion of RNA sequencing for detection of fusion genes is critical for evaluation of these tumors. Patients with fusion positive tumors were more likely to have features of high-risk disease.

Introduction:

Papillary thyroid carcinoma (PTC) accounts for 90% of thyroid malignancies in children and is especially prevalent among females aged 15-19 years, in whom it is the second most common malignancy¹. Pediatric PTC patients are more likely to present with metastatic disease and have a higher likelihood of relapse as compared to their adult counterparts²,³. Standard therapy for pediatric PTC most often involves total thyroidectomy (+/- lymph node dissection) as well as radioactive iodine therapy (RAI) for selected cases. While the prognosis for patients who have undergone standard therapy is excellent, with a 15-year overall survival of 95% ², there is significant morbidity secondary to surgical procedures and radiation exposure ⁵.

Much of our knowledge regarding the genomic landscape of PTC can be attributed to The Cancer Genome Atlas (TCGA) project, which comprehensively analyzed 496 tumors and matched germline samples. This study revealed that adult PTC is characterized by a relatively quiet genome with mutually exclusive driving
somatic genetic alterations in the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-
kinase (PI3K) pathways. However, as only 5 of the samples analyzed were from patients less than 19 years
of age, the extent to which these findings are applicable to childhood PTC was not known. Instead, our
understanding of the genomic landscape of pediatric PTC and corresponding clinical correlations relies on
data generated from smaller pediatric cohorts analyzed by varying molecular methods.

These pediatric studies suggest that point mutations regularly found in adult PTC, such as \textit{BRAF} V600E,
are identified less frequently in children, whereas gene fusions are more common\textsuperscript{1,7-9}. Other studies note a
correlation between the prevalence of oncogenic alterations and patient age, attributed to the more frequent
presence of the \textit{BRAF} V600E mutation in older patients\textsuperscript{10}. Unlike in adults, the presence of a \textit{BRAF} V600E
mutation in pediatric patients does not necessarily correlate with a more aggressive phenotype\textsuperscript{11,12}. Rather,
recent papers have suggested that pediatric thyroid tumors driven by fusion genes, such as \textit{RET/PTC1} and
\textit{NTRK3-ETV6}, may be correlated with more invasive disease\textsuperscript{13,14}.

Analysis from the Chernobyl nuclear accident helped delineate some of the differences between radiation-
induced and sporadic pediatric PTCs. Ricarte-Filho \textit{et al} found that radiation-induced pediatric PTCs
have an increased prevalence of fusion oncogenes compared to sporadic tumors, with the vast majority of
these fusions targeting genes (\textit{RET}, \textit{NTRK1} and \textit{NTRK3}, \textit{BRAF}) that activate the MAPK signaling
pathway\textsuperscript{15}. \textit{RET} rearrangements are also common in sporadic pediatric PTC, however, with rates ranging
from 17% to 58\%\textsuperscript{13-16}. Additionally, sporadic pediatric PTCs have been observed to have a larger number
of point mutations compared to radiation-induced PTCs, particularly in \textit{BRAF} and \textit{RAS} genes\textsuperscript{15,17}.

While each of these studies has provided additional insight into the nature of pediatric PTC, the molecular
methods utilized have varied significantly and largely relied on targeted analysis of known PTC genes.
We sought to perform more extensive DNA and RNA-based sequencing of a cohort of clinically-annotated
tumors, with a specific focus on patients with metastatic, relapsed or refractory disease, in order to identify
genetic alterations that might inform improved diagnostic and therapeutic approaches for these patients.

Materials and Methods:

Patients

Potential cases of PTC were identified through review of the Texas Children’s Hospital pathology archives
for the years 2005-2016, under a Baylor College of Medicine Institutional Review Board-approved protocol
for clinical and genomic analysis of rare tumors. A total of 51 PTC cases were identified for clinical review,
with metastatic, relapsed, and treatment-refractory cases prioritized for analysis (Figure 1). Ultimately, 40
cases were selected, all of which were diagnostic (pre-treatment) specimens obtained from either lobectomy
or total thyroidectomy. Of note, 14 of the patients included in this cohort were also included in a prior study
that included more targeted gene testing (Supplemental Table S1)\textsuperscript{18}. Disease status was classified using the
American Joint Committee on Cancer TNM classification system for differentiated thyroid carcinoma, 7\textsuperscript{th}
edition, and risk level was assessed as outlined in the American Thyroid Association (ATA) management
guidelines for children with differentiated thyroid cancer\textsuperscript{19}.

Tumor Sequencing

A pathologist with specific expertise in thyroid tumors (N.M.Q.) examined the hematoxylin and eosin-stained
tumor slides to identify representative areas of tumor suitable for molecular testing. DNA and RNA were
extracted from FFPE tumor specimens according to the manufacturers’ protocols utilizing the QIAamp
DNA FFPE Tissue Kit (Qiagen) and the RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Ambion),
respectively. DNA and RNA were quantified by Qubit (Thermo Fisher Scientific), with RNA undergoing an
additional quality assessment by the quantitative PCR assay PreSeq (ArcherDx).

Of the original 40 cases selected for sequencing, 4 cases were excluded due to insufficient quantity and/or
quality of nucleic acids. Therefore, 36 tumor samples with adequate quantity and quality of nucleic acids for
sequencing were utilized for NGS library preparation. DNA NGS libraries were generated using a custom
hybridization capture panel (NimbleGen/Roche) designed to capture all coding exons of 124 genes associated
with pediatric solid tumors as well as the \textit{TERT} gene promoter\textsuperscript{20}. RNA NGS libraries were generated using the Oncology Research Panel (ArcherDx) that utilizes Anchored Multiplex PCR chemistry to capture gene fusion events involving 75 recurrently rearranged cancer genes\textsuperscript{21}. NGS libraries were sequenced 4- to 6-plex on an Illumina MiSeq using V2 and V3 chemistry, respectively, and de-multiplexed using \texttt{bcl2fastq v2.18.0.12} (Illumina), achieving approximately 2.2-4.4 million sequencing reads per sample. The resulting DNA FASTQ files were analyzed using a custom DNA bioinformatics pipeline that includes alignment by BWA v0.7.12\textsuperscript{22} (Wellcome Trust Sanger Institute) and deduplication and QC analysis by Picard v2.9.2\textsuperscript{23}. Variant calling was completed by NextGENe v2.4.1.2 (SoftGenetics) and Platypus v0.8.1\textsuperscript{24} (Wellcome Trust Centre for Human Genetics) for the detection of SNVs and short indels, with variant annotation by VEP v.89\textsuperscript{25} (Ensembl). Copy number analysis was performed using CNVkit v0.9.3\textsuperscript{26}. CNVkit performs circular binary segmentation on the normalized GC and target capture density bias corrected log2 difference of binned read depths, using on-target (average bin-size = 300bp) and off-target reads (average bin-size = 500,000bp), between the tumor sample and reference pooled-normal peripheral blood samples to identify genome-wide regions of CNVs. Gene-level deletions and amplifications were then derived using these copy number segments. RNA FASTQ files were analyzed by the Archer Analysis suite v4.1.0.6 (ArcherDx) with additional custom wrapper and text-processing scripts for the detection of gene fusion events.

\textbf{Statistical Analysis}

Fisher’s exact test was performed to test for the association of tumor alterations with specific clinical features. Samples were included in this analysis if a driver alteration, defined as a \textit{BRAF} V600E mutation or an oncogenic gene fusion, was identified. Samples sequenced using only one methodology (DNA testing or RNA testing) and without an identified driver alteration were not considered completely analyzed and therefore not included in this analysis.

\textbf{Results:}

\textit{Demographic and Clinical Characteristics}

Our cohort consisted of 36 patients with pediatric PTC. Of those, 34 were diagnosed between ages 8-19 years, with the majority of patients being 15-19 years (Table 1). The male-to-female ratio was 1:3. Metastasis to cervical lymph nodes occurred in 29 of the 36 patients (81%), of which 10 also had lung metastases (28%). Tumor relapse post-surgery occurred in 18 of the patients (50%). In addition, while the majority of our cohort was comprised of patients without prior history of irradiation, we did include 8 patients (22%) who had undergone radiation therapy, including 2 patients with a history of Hodgkin lymphoma and 4 patients who received whole body irradiation prior to bone marrow transplant. The time from prior radiation to diagnosis of thyroid cancer ranged from 6 to 18.5 years (median 10.9 years). All patients underwent surgical resection of the thyroid gland, and 34 of 36 received RAI (94%). Tumors ranged in size between 0.2-7 cm, with a median size of 2.2 cm.

\textit{DNA Mutation Panel Testing}

DNA sequencing for mutation and copy-number profiling was successfully completed for 31 cases (Figure 1), revealing 10 cancer gene mutations in 9 tumor samples (29%; Figure 2). The most common mutation identified was \textit{BRAF} p.V600E, found in six tumors (19%) including one tumor with a co-occurring \textit{AKT1} p.E17K mutation, a known hotspot driver mutation in the PI3K pathway that has been identified in multiple cancer types, including in PTC\textsuperscript{27-29}. Other alterations identified included a \textit{PTPN11} hotspot mutation (p.S502T), a frameshift mutation in \textit{PIK3R1} (p.Y29fs), and a nonsense mutation in \textit{TP53} (p.Y163X). The genome-wide copy number profiles for these tumor samples did not reveal high level amplifications or homozygous losses (Supplemental Figure S1).

\textit{RNA Fusion Panel Testing}

RNA fusion panel testing was successfully completed for 25 cases (Figure 1), revealing fusions in 13 tumor samples (52%; Figure 2). The majority of these (n=8) were activating \textit{RET} kinase fusions, including the well-known \textit{NCOA4-RET} fusions (also known as \textit{RET/PTC3}) in 5 cases, and \textit{CCDC6-RET} (also known
as RET/PTC1) in 3 tumors (Figure 3). Four other tumors harbored NTRK3 fusions, including two ETV6-NTRK3 fusions, one EML4-NTRK3 fusion, and a novel VIM-NTRK3 fusion in one sample. Finally, one tumor was found to harbor a MACF1-BRAF fusion. All fusion genes identified retained the kinase domains of the oncogenic partners (RET, NTRK3, BRAF).

Clinical Associations

Driver alterations were found to be associated with cervical metastases or N1 classified lymph node samples ($P = 0.05, 19/23$; Figure 4a). The presence of an activating kinase gene fusion correlated with higher ATA risk level ($P = 0.027, 10/13$ high-risk patients; Figure 4b) and multifocal disease pathology ($P = 0.039, 13/22$ multifocal tumors; Figure 4c). BRAF V600E mutations were more frequent in smaller tumors (T1 and T2), while fusions were more frequent in larger tumors, T2 and higher ($P = 0.001$; Figure 4d).

Discussion:

Integrated DNA/RNA panel sequencing successfully identified frequent clinically-relevant alterations in a cohort of pediatric PTC patients enriched for metastatic and relapsed/refractory disease. Overall, BRAF V600E mutations were present in 19% of samples (6/31), consistent with other recent pediatric studies that have reported frequencies ranging from 17-61%\cite{1,11,14,17,30,31}. In contrast with adult PTC, fusions were detected more than twice as frequently as BRAF V600E mutations in our cohort, with activating kinase fusions detected in 52% of samples tested (13/25). All but one of the driver alterations detected in this cohort were mutually exclusive (a single driver alteration per patient). This is consistent with our understanding of adult PTC development, in that these tumors usually arise from a single molecular driver whose alteration causes continuous activation of MAPK and PI3K signaling pathways\cite{6,7}.

Fusion positive patients were more likely to be classified as ATA high-risk status and to have multifocal disease, findings that hold implications for future molecular testing. These patients are more likely to develop relapsed/recurrent disease requiring repeat surgery or RAI treatments. In comparison, patients with BRAF V600E mutations often presented with smaller primary tumors (T1 and T2) than those with fusion positive disease, although they frequently were found to have cervical lymph node metastasis at the time of diagnosis.

Employing the partner agnostic Oncology Research Panel (ArcherDx) enabled us to identify multiple unexpected fusions in our cohort. For example, three tumors were found to harbor fusions not known to be previously reported in PTC, including the patient with a novel VIM-NTRK3 fusion. A second patient was discovered to have PTC containing an EML4-NTRK3 fusion. This fusion has been identified in patients with infantile fibrosarcoma\cite{32,33}, but not previously in PTC. Interestingly, this patient had a prior history of recurrent osteosarcoma and later developed malignant melanoma, and was found to have Li-Fraumeni Syndrome by targeted TP53 clinical testing; this was not detected in our analysis as the DNA panel testing was not successful. Finally, a MACF1-BRAF fusion was identified in a third patient who had previously been diagnosed with AML and received radiation prior to bone marrow transplant; this fusion is novel in PTC and has been rarely reported in low grade glioma\cite{34}.

Our cohort contained a number of individual patients with notable genomic and clinical findings. For instance, a patient with a history of short stature and delayed puberty was found to have tumor containing a PTPN11 hotspot mutation (p.S502T) with a variant allele frequency of 50%. Although a blood sample was not available for germline testing, this mutation has previously been detected in patients with Noonan's syndrome\cite{35}. Another patient – the only case with two driver alterations detected - was found to have BRAF and AKT1 mutations at different variant allele frequencies (37% and 22%, respectively) in their tumor sample, suggesting that the AKT1 mutation was present in a sub-clonal population of the tumor.

Importantly, the vast majority of the alterations identified in our cohort are currently targetable with FDA-approved or investigational agents, including MAPK pathway inhibitors, PI3K pathway inhibitors, and other kinase inhibitors. Vemurafenib, a potent BRAF inhibitor that is specific for tumors with the BRAF V600E mutation, has shown antitumor efficacy in adults with progressive metastatic, RAI-refractory BRAF V600E
positive PTC\textsuperscript{36,37}. While its use in pediatric patients has generally been limited, in part due to the difficulty of studying adequate numbers of pediatric PTC patients in clinical trials\textsuperscript{38}, there are a number of case reports of children with \textit{BRAF} V600E positive tumors whose disease responded to treatment\textsuperscript{39-41}. One recently FDA approved agent is larotrectinib, a highly selective small molecule inhibitor of the tropomyosin receptor kinase (TRK) proteins (encoded by kinase genes \textit{NTRK1}, \textit{NTRK2}, and \textit{NTRK3}) which has demonstrated potent antitumor efficacy in both children and adults with TRK fusion positive tumors\textsuperscript{42,43}. Notably, TRK fusion positive tumors comprised approximately 11% (4/36) of our cohort. Results from a phase I trial included two pediatric patients with TRK (\textit{NTRK1} and \textit{NTRK3}) fusion-positive PTC; while these two patients could not be objectively evaluated by RECIST criteria (as they did not have measurable disease at enrollment), both patients remained on treatment without progression at the data cutoff point over 7 months later\textsuperscript{43}. Multiple targeted agents have been developed for adult patients with RET driven solid tumors. Sorafenib and lenvatinib, multi-kinase inhibitors that target \textit{RET}, \textit{FLT1}, \textit{KDR}, \textit{FLT4}, \textit{PDGFR\alpha}, \textit{PDGFR\beta}, and \textit{KIT}, are FDA approved for adults with PTC and \textit{RET} fusions\textsuperscript{44}. Sorafenib has been studied in a phase 2 trial in pediatrics but no PTC patients were enrolled on study\textsuperscript{45}. A recent report of three pediatric patients with refractory PTC who demonstrated clinical improvement with lenvatinib suggests that this may also be of potential utility in relapsed or refractory patients\textsuperscript{46}. Additionally, selpercatinib, an oral and selective investigational drug targeting RET kinase abnormalities, was recently FDA approved for patients ages 12 and older with metastatic or advanced \textit{RET}-mutated medullary thyroid carcinoma or \textit{RET} fusion positive (and RAI refractory) thyroid cancer\textsuperscript{47}. Selpercatinib will soon be available to relapsed pediatric patients through the National Cancer Institute and Children’s Oncology Group jointly sponsored Pediatric MATCH trial\textsuperscript{48}. Of the 20 cases which were evaluated by both DNA and RNA NGS panels, potentially clinically-relevant alterations were detected in 15 cases (75%). The frequency of driver alterations in metastatic and relapsed/refractory pediatric PTC, in combination with a steady increase in available molecularly targeted agents and the need to decrease morbidity from repeated surgeries and RAI treatments, has significant implications for the utility of molecular testing in this patient population. Our findings strongly support the inclusion of RNA testing in such analysis, especially in ATA high-risk patients where the diagnostic yield is particularly high. Given the potential therapeutic importance of identifying targetable gene fusions which are often characterized by diverse and novel gene partners, methods that enable partner-agnostic detection of fusion genes, such as anchored multiplex chemistry (used in this study to detect a novel \textit{VIM-NTRK3} fusion) or capture-based transcriptome sequencing should be preferred. At our center, we clinically test all relapsed and/or refractory pediatric patients with PTC using paired targeted DNA/RNA cancer gene panels as described above, and recommend upfront tumor testing in patients who are not amenable to conventional management, including RAI therapy, or who have symptomatic lung disease; however, a stepwise approach, in which such patients are first evaluated for \textit{BRAF} V600E mutations, and if negative, undergo fusion testing, is a reasonable alternative.

In conclusion, our experience suggests that targeted DNA mutation and RNA fusion panel sequencing for pediatric patients with ATA high-risk PTC has the potential to be of clinical benefit, especially with the recent increase in available targeted agents for pediatric patients. We anticipate that as we continue to attempt to minimize morbidity associated with repeated RAI exposure and surgery for these patients, utilization of molecularly targeted agents in conjunction with current standard therapies will increase, particularly amongst patients with lung metastases and refractory disease. Additionally, as our cohort consisted of pretreatment specimens obtained from thyroidectomy, further studies evaluating the degree of tumor evolution over time and necessity for re-biopsy will be needed.

\textbf{Financial Support:} Dr. Samara Potter is funded by a Paul Calabresi Scholar K12 Career Development Award, a St. Baldrick’s Foundation Fellowship Award, and the Gillson Longenbaugh Foundation. Mr. Raghu Chandramohan is funded by the Gillson Longenbaugh Foundation and the Cullen Foundation. Dr. Will Parsons is the recipient of a St. Baldrick’s Innovation Award.
Author Disclosure Statement: Dr. Potter serves as a consultant for Bayer Healthcare Pharmaceuticals.

Acknowledgements: We would like to acknowledge our patients and their families and the members of the Thyroid Tumor Program at Texas Children’s Hospital. We are grateful to the St. Baldrick’s Foundation, the Gillson Longenbaugh Foundation, and the Cullen Foundation for their financial support for this manuscript.

Data sharing: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References:


47. ClinicalTrials.gov. Identifier NCT03157128: Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001). Bethesda (MD) 2018.


Legends:

**TABLE 1.** Demographic and clinical characteristics of pediatric PTC cohort

**Figure 1.** Flowchart demonstrating cohort selection and sequencing. PTC, papillary thyroid carcinoma.

**Figure 2.** Oncoprint illustrating genomic sequencing findings and selected clinical characteristics.

**Figure 3.** Fusions detected by RNA panel sequencing (A) *NCOA4-RET* (B) *CCDC6-RET* (C) *ETV6-NTRK3* (D) *VIM-NTRK3* (E) *EML4-NTRK3* (F) *MACF1-BRAF*. All fusions retain the protein kinase domain.

**Figure 4.** Distribution of driver alterations (gene fusions and *BRAF* V600E mutations) with various clinical characteristics, including (A) cervical lymph node metastases, (B) ATA risk level, (C) primary tumor focality, and (D) extent of primary tumor.

**Supplemental Table S1.** Cohort clinical and genomic data

**Supplemental Figure 1.** Copy number variant heatmap

**Hosted file**

*Potter Thyroid Manuscript Table 1.docx* available at https://authorea.com/users/330102/articles/456981-integrated-dna-and-rna-sequencing-reveals-targetable-alterations-in-metastatic-pediatric-papillary-thyroid-carcinoma
Non-metastatic (n=11)
Poor quality (n=4)
Clinically aggressive PTC (n=40)
PTC samples sequenced (n=36)
DNA only sequenced (n=11)
Both DNA/RNA sequenced (n=20)
RNA only sequenced (n=5)

Prior Radiation
Cervical Metastasis
Lung Metastasis
Relapse

RET
BRAF
NTRK3
PIK3R1
TP53
PTPN11
AKT1

Sequencing

Clinical Features
Yes
No

Alterations
<table>
<thead>
<tr>
<th>DNA only</th>
<th>DNA only</th>
<th>Both</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activating mutation</td>
<td>Fusion</td>
<td>Inactivating mutation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>DNA only</th>
<th>DNA only</th>
<th>Both</th>
</tr>
</thead>
</table>